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Abstract 16 
Influenza virus infection is a significant global health threat. Because of the lack of cross protective 17 
universal vaccines, short time window during which antivirals are effective and drug resistance, new 18 
therapeutic anti-influenza strategies are required. Broadly cross-protective antibodies that target 19 
conserved sites in the hemagglutinin (HA) stem region, have been proposed as therapeutic agents. FI6 20 
is the first proven such monoclonal antibody to bind to H1-H16 and is protective in mice and ferrets. 21 
Multiple studies have shown that Fc-dependent mechanisms are essential for FI6 in vivo efficacy. Here 22 
we show that therapeutic administration of FI6 either intravenously or by aerosol to pigs did not reduce 23 
viral load in nasal swabs or broncho-alveolar lavage, but aerosol delivery of FI6 reduced gross 24 
pathology significantly. We demonstrate that pig Fc receptors do not bind human IgG1 and that FI6 25 
did not mediate antibody dependent cytotoxicity (ADCC) with pig PBMC, confirming that ADCC is 26 
an important mechanism of protection by anti-stem antibodies in vivo.  Enhanced respiratory disease, 27 
which has been associated in pigs with cross-reactive non-neutralising anti-HA antibodies, did not 28 
occur after FI6 administration. Our results also show that in vitro neutralizing antibody responses are 29 
not a robust correlate of protection for the control of influenza infection and pathology in a natural host 30 
model.   31 
Introduction 32 
Influenza virus infection and immunization induce protective antibody responses. A major part of the 33 
antibody response is directed at the hemagglutinin (HA) glycoprotein.  Influenza HA is composed of 34 
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two domains: the immunodominant globular head, which is strain specific and the stalk which is 35 
relatively conserved within each subtype.  Seasonal immunization induces antibodies predominantly 36 
against the globular head which neutralize the immunizing strain very effectively, but escape variants 37 
rapidly emerge and are responsible for antigenic drift. In the last decade influenza-neutralizing 38 
antibodies that target conserved sites in the HA stem of influenza A viruses (IAVs) have been described 39 
and these show cross-reactivity between group 1 and group 2 viruses (1-7). Anti-stem antibodies are 40 
less potent at direct viral neutralization as compared to anti-head antibodies, but they mediate 41 
protection in vivo through Fc-dependent effector functions, which can be assessed in vitro by 42 
measuring antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxiticy 43 
(CDC) or antibody-dependent cellular phagocytosis (ADCP) (4, 8, 9). FI6 was the first proven broadly 44 
neutralizing antibody to be described, capable of recognizing the HAs of all 16 subtypes and 45 
neutralizing both group 1 and 2 IAVs (4). Passive transfer of FI6 conferred protection in mice and 46 
ferrets. It has been proposed that such broadly cross-reactive antibodies might have potential as 47 
therapeutic agents for treatment of severe influenza and several are tested in clinical trials (10, 11).  48 
A potential problem of developing such antibodies as immune therapeutics is enhanced respiratory 49 
disease and increased pathology, associated with immune complexes of low avidity or non-neutralizing 50 
antibodies. Vaccine-associated enhanced respiratory disease (VAERD) has been observed in pigs when 51 
heterologous IAV infection occurs after immunization with mismatched whole inactivated vaccine 52 
(WIV) (12-15). VAERD was associated with the presence of high titer cross-reacting non-neutralizing 53 
antibodies targeting the conserved stem domain at a site adjacent to the fusion peptide. In the absence 54 
of neutralizing antibodies against the globular head of H1N1pdm09, stem antibodies were associated 55 
increased virus infection of MDCK cells in vitro and enhanced membrane fusion (16).  56 
As both pigs and humans are readily infected with IAVs of similar subtype, the pig is an appropriate 57 
model for investigating both swine and human disease. Like humans, pigs are outbred, and 58 
physiologically, anatomically and immunologically similar to humans. The porcine lung also 59 
resembles the human in terms of its physiology, morphology and distribution of receptors bound by 60 
IAV (17, 18). Here we used the pig influenza model to test whether therapeutic administration of FI6 61 
would reduce or enhance disease.  62 
Materials and Methods 63 
Animals and influenza virus challenge  64 
Animal experiments were approved by the Pirbright Institute ethics committee, according to the UK 65 
Animal (Scientific Procedures) Act 1986.  Five to six week old landrace cross, female pigs were obtained 66 
from a commercial high health status herd. Pigs were screened for absence of IAV infection by matrix 67 
(M) gene real-time quantitative reverse transcriptase polymerace chain reaction (qRT-PCR) (19) and 68 
antibody-free status was confirmed using haemagglutination inhibition (HAI) with 4 swine IAV antigens 69 
– pandemic H1N1, H1N2, H3N2 and avian-like H1N1. Pigs weighed between 9 and 12 kg. All pigs were 70 
challenged with 1 x 107 plaque forming units (PFU) of A/sw/Eng/1353/09 (pdmH1N1) influenza virus 71 
strain. The pigs were inoculated by the intra-nasal route using a mucosal atomization device, MAD300 72 
(Wolfe Tory Medical) with 2ml of virus administered to each nostril. The virus was propagated in Madin-73 
Darby canine kidney (MDCK) cells. The challenged pigs were randomly divided into five groups of 5 74 
animals and received the following antibodies (experimental design in Fig 1A). 1) Control group – no 75 
treatment; 2) 15 mg/kg of FI6 antibody intra-venously (FI6 I.V.) in the ear vein at 1 day post infection 76 
(dpi); 3) 1.5 mg/ml FI6 antibody administered by aerosol (FI6 aer) using InnosSpire Mini (Philips 77 
Respironics  http://evergreen-nebulizers.co.uk/respironics/innospire_mini.html) with Aerogen mesh 78 
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3 
reservoir with an airspeed of 2 L/min at 1 and 2 days post infection (dpi); 4) 15 mg/kg of EVB114 79 
antibody I.V. in the ear vein at 1 dpi and 5) 1.5 mg/kg of the MPE8 antibody by aerosol at 1 and 2 dpi as 80 
described above. All antibodies were provided by Humabs BioMed. They were produced in Chinese 81 
hamster ovary (CHO) cells,  affinity-purified using HiTrap Protein A columns (GE Healthcare) followed 82 
by desalting using HiTrap Fast desalting columns (GE Healthcare). The final product were sterilized by 83 
filtration through 0.22 μm filters and stored at +4°C until use. Antibodies were diluted in phosphate 84 
buffered saline (PBS) to the desired concentration before administration. Animals were monitored by 85 
observing demeanour, appetite and respiratory signs such as coughing and sneezing.  86 
Gross pathology and histopathological scoring of lung lesions  87 
Animals were humanely killed 4 dpi with an overdose of pentobarbital sodium anaesthetic. At post 88 
mortem the lungs were removed and digital photographs taken of the dorsal and ventral aspects. 89 
Macroscopic pathology scoring was performed blind using Nikon-NIS Br software to determine the 90 
proportion of the total surface area of each lung lobe affected by typical influenza-like gross lesions. Five 91 
lung tissue samples per animal from the right lung (2 pieces from apical lobe, 1 from the medial, 1 from 92 
the diaphragmatic and 1 from the accessory) were collected into 10% neutral buffered formalin for 93 
routine histological processing at the University of Surrey. Formalin fixed tissues were paraffin wax-94 
embedded and 4-m sections were cut and routinely stained with haematoxylin and eosin. 95 
Histopathological changes in the stained lung tissue sections were scored by a veterinary pathologist 96 
blinded to the treatment group. Lung histopathology was scored using five parameters (necrosis of the 97 
bronchiolar epithelium, airway inflammation, perivascular/bronchiolar cuffing, alveolar exudates and 98 
septal inflammation) scored on a 5-point scale of 0 to 4 and then summed to give a total slide score 99 
ranging from 0 to 20 and a total animal score from 0 to 100. Scoring criteria were based upon a previously 100 
published method  (20).  101 
Tissue sample processing  102 
Four nasal swabs (NS) (two per nostril) were taken at 0, 1, 2, 3, 4 dpi. The swabs were placed into 2 ml 103 
of virus transport medium comprising tissue culture medium 199 (Sigma-Aldrich) supplemented with 104 
25mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 0.035% sodium bicarbonate, 0.5% 105 
bovine serum albumin (BSA), penicillin 100 IU/ml, streptomycin 100 µg/ml and nystatin 0.25 µg/ml, 106 
vortexed, centrifuged to remove debris and stored at -80oC for subsequent virus titration. Serum samples 107 
were collected at the start of the study (prior to challenge) and at 2 and 4 dpi. For Fc binding and ADCC 108 
assays blood from healthy humans and uninfected pigs was used. Heparinized blood samples were diluted 109 
1:1 in PBS before density gradient centrifugation. PBMC were harvested from the interface, washed and 110 
red blood cells lysed with ammonium chloride lysis buffer, washed again and used in Fc binding and 111 
ADCC assays described below. Broncho-alveolar lavage (BAL) was collected from the entire left lung 112 
with 150ml of virus transport medium (described above). BAL samples were centrifuged at 300 x g for 113 
15 minutes, supernatant was removed, aliquoted and frozen for antibody analysis.  114 
Virus titration  115 
Viral titers in nasal swabs and BAL were determined by plaque assay on MDCK cells. Duplicate samples 116 
were 10-fold serially diluted in Dulbecco’s modified Eagles medium (DMEM) and 100 l of each 117 
dilution added to confluent MDCK cells in 12 well tissue culture plates. After 1 hour, the plates were 118 
washed and overlayed with 2 ml 1:3 2% (w/v) agarose:medium. Plates were incubated at 37°C for 48 119 
hours, plaques visualized by staining the monolayer with 0.1% (v/v) crystal violet and enumerated. RNA 120 
was extracted using the QIAamp viral RNA mini kit (Qiagen) according to the manufacturer’s protocol 121 
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and viral titers in nasal swabs and BAL fluid was also determined by real-time qRT-PCR amplification 122 
of the M gene using PCR conditions as previously described (21). Forward primer sequence AGA TGA 123 
GTC TTC TAA CCG AGG TCG, reverse primer sequence TGC AAA GAC ACT TTC CAG TCT CTG 124 
and probe sequence FAM-TCA GGC CCC CTC AAA GCC GA-TAMRA  125 
Enzyme-linked immunosorbent assay (ELISA)  126 
Human IgG1 antibody levels in serum and BAL fluid were determined by IgG1 Ready-SET-Go! ELISA 127 
(Affymetrix, eBioscience) according to the manufacturer’s instructions. After heat inactivation (56oC for 128 
30 min) samples were diluted 1:40 (serum) and 1:2 (BAL fluid). Influenza-specific human Ab titers in 129 
serum and BAL fluid were determined by ELISA as previously described (20) with the following 130 
modifications. The IgG ELISA was performed in 96-well ELISA plates (BD Biosciences) coated with 131 
1x106 PFU/ml of A/swine/England/1353/09 over night at 4°C. Two-fold dilutions of BAL fluid samples 132 
or serum (heat inactivated for 30 min at 56°C) were added, starting from 1:2 or 1:10 dilution respectively. 133 
Binding of influenza specific Abs was detected using a monoclonal anti-human IgG (Fc) (Biorad) and 134 
3,3',5,5'-tetramethylbenzidine (TMB) substrate (BioLegend). Optical density (OD) readings were taken 135 
at 450 and 570 nm (wavelength correction). Ab values were expressed as endpoint titers defined as the 136 
highest dilution at which the OD was higher than twice the background OD. 137 
Fc binding 138 
To determine if FI6 was able to bind pig Fc receptors FI6, MPE8 and serum from influenza negative and 139 
immune (14 dpi) animals were incubated at 37°C for 1 hour with and without influenza virus. Human 140 
and pig PBMC were added and incubated for a further hour at 4°C. Human PBMC were stained with 141 
near-infrared fixable Live/Dead (Invitrogen) and anti-human IgG AF488 (HP6017, Biolegend) for 20 142 
minutes at 4°C. Pig PBMC were stained with near-infrared fixable Live/Dead (Invitrogen), CD3 AF647 143 
(BB23-8E6-8C8, BD), CD8α Pe (76-2-11, BD) anti-human IgG or anti-pig IgG FITC (BIO-RAD). 144 
Samples were run on a BD LSR Fortessa and data analysed using FlowJo (Treestar). 145 
Entry microneutralization assay 146 
Serum and BAL fluid were heat inactivated at 56°C for 30 minutes, serially diluted 1:2 in 50µl PBS, 147 
starting dilution 1:40 for serum and 1:4 for BALF, before addition of 50µl green-fluorescent protein 148 
(GFP) - H1 virus diluted in virus growth medium (22). Following incubation for 2 hours at 37°C 3×104 149 
indicator MDCK-SIAT1 cells were added in a volume of 100µl virus growth medium without trypsin 150 
and incubated overnight at 37°C. Plates were fixed using 4% paraformaldehyde and GFP fluorescence 151 
intensity (FI) was measured at an excitation of 483 nm and an emission of 515 nm. Serum and BALF 152 
from animals 14 days post influenza challenge and purified FI6 antibody were included as positive 153 
controls. 154 
Antibody-dependent cell-mediated cytotoxicity (ADCC) assay  155 
MDCK- 2,6-sialtransferase (SIAT1) stably transduced with the lentiviral vector pHR-SIN engineered to 156 
express the full-length open-reading frame (ORF) of HA from A/Eng/195/2009 were used as target cells 157 
for the ADCC assay (22). The HA from A/Eng/195/2009 differs by a single exposed residue at D222G 158 
from the Eng/1353 that was used to challenge the pigs. MDCK-HA cells were seeded in round-bottom 159 
96 well plates and incubated with different dilutions of heat-inactivated serum (1:10, 1:20, 1:40, 1:80 or 160 
1:160) or with different amounts of antibody (FI6 or MPE8) for 10 min at 37C. After that freshly-isolated 161 
human or pig PBMCs from healthy donors or animals respectively, were added in a 20 to 1 E:T ratio to 162 
the 96 well plates and incubated for 4h at 37ºC. MDCK-HA and PBMC were cultured in serum-free 163 
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5 
AIM-V medium (Life Technologies, UK). At the end of the incubation period 100 µl of cell-free 164 
supernatant was transferred into a flat-bottom 96 well plate and the Lactate dehydrogenase (LDH) release 165 
measured with the Cytotoxicity Detection Kit from Roche according to the manufacturer’s instructions. 166 
The absorbance was measured at 490 nm and 620 nm in a plate reader. When the purified antibodies 167 
MPE8 and FI6 were used the percentage of cytotoxicity on the Y-axis was calculated with the formula: 168 
[Sample at each immune antibody dilution with target cells and PBMC minus control antibody at the 169 
same dilution with target cells and PBMC] divided by [maximum release of target cells and PBMC in 170 
the presence of detergent minus control target and effector spontaneous release without antibody] x 100. 171 
In assessing the ADCC activity of serum samples, the percentage of cytotoxicity was calculated as 172 
described above but using the naïve sera (corresponding dilution to sera of immunized pigs to calculate 173 
the spontaneous release). 174 
Statistical analysis  175 
One-way non-parametric ANOVA (Kruskall-Wallis) with Dunn’s post-test for multiple comparisons 176 
was performed using GraphPad Prism 6.   177 
Results 178 
Lung pathology and viral load after antibody administration 179 
In order to determine the therapeutic effect of FI6 antibody in the pig influenza model, FI6 was 180 
administered I.V. at 15 mg/kg 1 day post infection (dpi). The ebola virus specific antibody, EVB114 181 
was used as a control and delivered at the same concentration I.V. (23). We also administered FI6 as 182 
an aerosol (aer) as this route of delivery is highly efficient in targeting the respiratory tract, which is 183 
the site of entry and infection of IAV (20, 24-28). We administered 10 times less FI6 by aerosol (1.5 184 
mg/kg) at 1 and 2 dpi. As a control for the aerosol delivery we used MPE8, which is a broadly-185 
neutralizing antibody for human respiratory syncytial virus (HRSV), human metapneumovirus 186 
(HMPV), bovine RSV (BRSV) and pneumonia virus of mice (PVM) but not IAV (29) (Fig. 1A). All 187 
of the mAbs were monoclonal, fully human IgG1. The clinical signs observed were mild and none of 188 
the pigs developed moderate or severe disease. The control group showed the most severe gross and 189 
histopathology (Fig. 1B). A reduction in the gross and histopathology score was observed in all the 190 
mAb treated groups. However, this reduction was statistically significant only in gross pathology for 191 
the FI6 aer group. Interestingly despite the reduced lung pathology, there were no differences in viral 192 
load in nasal swabs at 1, 2, 3 and 4 dpi (Fig. 2A) or in the broncho-alveolar lavage (BAL) at the time 193 
of sacrifice at 4 dpi (Fig. 2B) as determined by plaque forming assays and PCR. This is in contrast 194 
with previous studies in mice and ferrets where FI6 administration significantly reduced viral load in 195 
the lungs (4). 196 
These results indicate that administration of therapeutic FI6 to pigs did not reduce viral load in NS or 197 
BAL but also it did not exacerbate disease as previously shown with anti- stem antibody (16). The 198 
mAb treated groups showed reduced pathology, although the reduction was significant only for the aer 199 
FI6 group. The reduced pathology is also observed using control antibodies, a finding that might be 200 
related to the anti-inflammatory and immunomodulatory activities of human IgG1 Fc. Indeed, it has 201 
been shown that the anti-inflammatory activity of human intravenous immunoglobulin   is dependent 202 
on sialylation of the N-linked glycan of the IgG1 Fc fragment (30, 31).  203 
Influenza binding and neutralizing activity of administered antibodies 204 
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ELISA for hum IgG1 confirmed that all antibodies were delivered successfully, albeit the control 205 
EVB114 was detected at a lower concentration in the serum perhaps due to differences in the catabolic 206 
rates of this mAb. The mAb concentrations declined at 4 dpi compared to 2 dpi, but were still ~107 207 
g/ml for FI6 and ~45 g/ml for EVB114 (Fig. 3A). Aerosol administration of FI6 and MPE8 did not 208 
result in detectable quantities of mAbs in the serum. However, mAbs were detected in BAL, with ~ 209 
6.5 g/ml for FI6 and 0.5 g/ml for MPE8 measured at 4 dpi, 2 days after the last aerosol 210 
administration, most likely indicating that the mAbs are catabolized rapidly after aerosol delivery (Fig. 211 
3A). Furthermore I.V. FI6 delivery resulted in the presence of ~ 0.33 g/ml in the BAL 4 days after 212 
the administration of the antibody, approximately 20 fold less as compared to the aer FI6 group. To 213 
further confirm the presence and specificity of FI6 after delivery, virus specific ELISA was performed 214 
with the challenge virus. As expected influenza specific human  mAb was detected in serum after FI6 215 
I.V. delivery at both 2 and 4 dpi, while in BAL a higher titer was seen after aerosol (1:84) compared 216 
to FI6 I.V. administration (1:24) (Fig. 3B). 217 
To determine whether the FI6 in the serum and BAL was still able to neutralize the virus, which might 218 
explain the lack of reduction of viral titer, we performed entry virus neutralization using MDCK cells 219 
transfected with H1 HA. The serum from the FI6 I.V. group was neutralizing at both 2 and 4 dpi with 220 
a mean 50% inhibitory titer of  1:812 at 2 dpi and 1:448 at 4 dpi (Fig. 4A and B), comparable to control 221 
immune pig serum. In the BAL of the FI6 aer group the mean 50% inhibitory titer was 1:10 at 4 dpi 222 
and in the FI6 I.V. group 1:3.4 (although only 2 out of the 5 animals had positive results) (Fig 4A and 223 
C). The neutralization values for the BAL were lower than a control BAL fluid (1:640) from a pig 224 
sacrificed 14 days post challenge with the same virus. No neutralization was detected in the animals 225 
receiving control antibodies or in the untreated controls. Pre-challenge sera from FI6 treated animals 226 
and BAL from control animals did not show any neutralizing activity (Fig. 4D). 227 
Overall these results indicate that the mAbs were successfully delivered and retained their influenza 228 
binding and neutralizing activity as measured in vitro.   229 
Fc binding and ADCC  230 
As it has been shown convincingly that most broadly neutralizing anti-IAV mAbs mediate their in vivo 231 
effect through antibody effector functions (4, 9, 32) we next asked whether the FI6 or human IgG1 can 232 
bind pig FcR and mediate ADCC. Fc binding was assessed after pre-incubating the mAbs with 233 
pdmH1N1 virus in order to form immune complexes. As expected human lymphocytes bound FI6 with 234 
74% of the lymphocytes stained compared to less than 2% for the controls (Fig. 5A). In contrast, 235 
minimal binding of FI6/pdmH1N1 to pig PBMC was detected. A more detailed analysis was performed 236 
by gating on pig NK cells, defined as CD3-CD8+ (Fig. 5B and C), which bound immune pig serum 237 
pre-incubated with pdmH1N1, but bound very little FI6 (51.8% for immune pig serum versus 2.37% 238 
for FI6). Similar results were obtained after detection of immune complexes with secondary anti-239 
human IgG, indicating that this antibody could bind the pig Ig (Fig. 5C). 240 
Finally, to determine whether FI6 can mediate ADCC in pigs we evaluated killing by LDH release 241 
from MDCK cells stably transfected with H1 HA. As previously described FI6 was able to mediate 242 
ADCC with human PBMC as effector cells (Fig. 6), but not with pig PBMC. Immune pig serum from 243 
influenza infected or immunized pigs gave specific killing. 244 
These results suggest that the failure of FI6 to protect against influenza infection in pigs is most likely 245 
due to the inability of FI6 to bind pig FcR and mediate ADCC, and possibly other effector functions 246 
(e.g. ADCP). 247 
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Fc binding sites in human, mouse, and pig FcRs and IgG subclasses  248 
The apparent failure of FI6 to interact functionally with pig FcR led us to compare the putative binding 249 
sites on both the FcRs and the Fc portion of IgG. Importantly, crystallographic analyses of human IgG 250 
(hIgG) complexed with human FcRIII and the structure for human FcRI have elucidated the 251 
important contact sites for this interaction (33-36). On the receptor, the Fc contact sites are spread 252 
across the second immunoglobulin domain, and most notably in the BC, C’E, and FG loops (Fig. 7A). 253 
Comparison of known mouse, human, and pig FcR sequences revealed species-specific variation 254 
within these regions, and does not immediately suggest that mouse FcRs would have greater affinity 255 
for hIgG than the pig (Fig. 7A). However, it has been shown that human IgG1 binds to mouse FcgRIV 256 
and effectively induces ADCC and ADCP with mouse NK cells, mouse polymorphonuclear 257 
leukocytes, and mouse macrophages (37). 258 
Among the hIgG subclasses, hIgG1 and hIgG3 bind most strongly to FcRs; whereas, hIgG2 and hIgG4 259 
bind either poorly or not at all (38). Notably on the Fc portion of the antibody, the lower hinge region, 260 
the hinge-proximal portion of the CH2 domain, and an N-linked glycosylation site in CH2 are 261 
implicated in Fc binding. In particular, the motif “LLGG” in the lower hinge is believed to play a 262 
crucial role (39-41). Indeed, mutation of this motif in hIgG1 to either “VLGG” or “LAGG” was 263 
previously shown to reduce or prevent binding to FcRI, respectively (42). In addition, the mutation of 264 
residues L234 and L235 to alanine to generate the so called LALA mutant abrogates binding to all FcR 265 
and C1q (43). Conversely, mutation of hIgG2 from “VAG” to “LLGG” and of hIgG4 from “FLGG” 266 
to “LLGG” restored FcRI binding to levels comparable to hIgG1 (42). Interestingly, mice have fully 267 
conserved this motif in mIgG2a, and have similar motifs in mIgG2b and mIgG3 (“LEGG” and “ILGG”, 268 
respectively) (Fig. 7B). Of the porcine IgGs, however, pIgG3 is most similar (“VLGA”), whereas the 269 
rest of the subclasses lack this motif, and are generally more similar to hIgG2 in this region. Thus, the 270 
presence of the canonical (“LLGG”) FcR binding motif in both human and mouse IgG, but not in pig 271 
IgG, suggests that porcine FcRs recognise the Fc portion of IgG differently than in humans and mice. 272 
Structural analysis revealed that the LLGG motif of human IgG1 interacts with hydrophobic residues 273 
(LVG) in the FG loop of the human FcRIIIB. Similarly, hydrophobic residues are found in human 274 
FcRIIIB and mouse FcRIV (LFG and LIG, respectively). Conversely, the pig FcRIII carries the IIK 275 
motif in the FG loop. The analysis of the interaction of the Fc of human IgG1 with human FcRIIIB 276 
indicates that the presence of a lysin at position 159, as found in the porcine FcRIIIB, would clash 277 
with L235, thus interfering with the favorable interaction of the LLGG motif of human IgG1 with the 278 
FG loop required for FcRIII binding (Fig. 7C). This observation might explain the lack of binding of 279 
human IgG1 FI6 to pig PBMCs. Of note, the hinge regions of all pig IgGs (except for pig IGHG3) are 280 
shorter as compared to human IgG1, a finding that might suggest a different modality of interaction of 281 
the pig Fcs with the cognate FG loop of porcine FcRIII.  282 
Discussion 283 
Our data shows that therapeutic administration of the broadly neutralizing FI6 antibody either 284 
intravenously or by aerosol to pigs did not result in exacerbation of disease. Aerosol delivery of FI6 285 
was the only treatment to reduce gross pathology significantly, although viral titers in nasals swabs or 286 
BAL were unchanged. We further demonstrated that the pig Fc receptors do not bind human IgG1 and 287 
that FI6 did not mediate ADCC with pig PBMC, suggesting that the pig is an inappropriate model to 288 
evaluate human IgG1 antibodies. 289 
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Previous studies have shown that all neutralizing and non-neutralizing anti-HA (and anti-290 
neuraminidase) mAbs that recognise a breadth of influenza strains require FcRs for protection in vivo 291 
(4, 9, 32), while strain specific mAbs did not. This suggests that the in vitro neutralization mechanism 292 
of broadly neutralizing mAbs such as inhibition of viral fusion or egress, do not dominate in vivo at the 293 
doses tested. Our results clearly demonstrate therefore that in vitro neutralising antibody responses are 294 
not a robust correlate of protection for the control of influenza virus infection and pathology in a natural 295 
host model.   296 
There are limited studies describing porcine FcRs. Although there is obvious overall similarity to their 297 
human and mouse counterparts, some FcR in domestic animals are unusual, perhaps most notably 298 
bovine Fcγ2R, which although related to other mammalian FcγRs, belongs to a novel gene family and 299 
porcine FcγRIIIA, which associates with a molecule that contains significant homology to the cathelin 300 
family of antimicrobial proteins (44, 45). Furthermore, the conservation of FcγR binding sites in human 301 
and mouse IgG, but not in pig IgG, is consistent with our findings. Clearly differences in interaction 302 
with IgG subclasses, cell type and tissue specific expression, as well as species differences should be 303 
considered when using these models for in vivo evaluation of therapeutic mAbs.  Substituting the 304 
human Fc portion of the FI6 antibody with a pig Fc would provide definitive proof of the importance 305 
of Fc binding and ADCC for therapeutic efficacy of FI6.   306 
It is clear that the delivery of FI6 did not cause pathology or exacerbation of disease as described by 307 
Khurana et al (16). In their study the pigs were immunized with a whole irradiation inactivated, 308 
adjuvanted H1N2 (human like virus) and challenged with a different pdmH1N109 strain. The authors 309 
suggested that the vaccine-induced anti-HA stem antibodies facilitated a conformational change in HA 310 
that enhanced its fusion and increased virus entry into cells in vitro. Nevertheless because FI6 does not 311 
engage FcR mediated effector mechanisms in pigs, it is still possible that these might contribute to 312 
VAERD, for example by massive killing of infected cells, leading to inflammation and pathology. 313 
In summary our data shows that therapeutic administration of FI6 or a control, either intravenously or 314 
by aerosol to pigs did not exacerbate disease. Aerosol delivery is an effective means of administration 315 
for therapeutic mAbs in large animals and possibly humans. FI6 does not bind to pig Fc receptors or 316 
mediate ADCC, confirming previous evidence that ADCC is an important mechanism for protection 317 
by anti-stem Ab in vivo.   318 
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Figure Legends 498 
Fig. 1. Experimental design and lung pathology. Pigs were infected with A/sw/Eng/1353/09 and 499 
received the indicated antibodies either by the I.V. route at 1 dpi or by aerosol at 1 and 2 dpi (A). The 500 
animals were sacrificed at 4 dpi and lungs scored for appearance of gross (B) and histopathologcial 501 
lesions (C). Each data point represents an individual within the indicated group and lines represent the 502 
mean. * denotes significant difference from the control group (P< 0.05).  Representative gross 503 
pathology of a pig from control group (D) and FI6 aer (E). 504 
Fig. 2. Viral load in nasal washes and BAL. Pigs were infected with A/sw/Eng/1353/09 and 505 
administered the indicated antibodies either by the I.V. route (I.V. solid symbols) or by aerosol (aer, 506 
hollow symbols). Nasal swabs (NS) were taken at 0, 1, 2 and 3 dpi and pigs sacrificed at 4 dpi. Viral 507 
titers in the nasal swabs (A) and BAL (B) were determined by plaque forming assay (PFU) or real-508 
time qRT-PCR. Each data point represents an individual within the indicated group and bars represent 509 
the mean. 510 
Fig. 3. Mucosal and systemic IgG responses following administration of antibodies. Human IgG1 511 
(A) and pdmH1N1 specific IgG (B) titers in serum at 0, 2 and 4 dpi and in BAL at 4 dpi. Note for 512 
pdmH1N1specific antibody in serum – all five pigs had titers of 1:640 at 4dpi, while 2 animals at 513 
1:1024 and three at 1:640 at 2dpi. 514 
Fig. 4. Entry eutralization activity of serum and BAL following administration of antibodies. A) 515 
Individual 50% inhibition titers in the serum at 0, 2 and 4 dpi and BAL at 4 dpi. B) Neutralizing 516 
antibody response measured in the serum of the pigs following FI6 I.V. administration at 2 and 4 dpi. 517 
C) Antibody response in the BAL of animals given FI6 I.V. or by aerosol at 4dpi. D) Negative sera 518 
from pre-challenge samples and negative BAL from control animals are shown alongside positive 519 
control. The dashed line represents the 50% inhibition titer and FI the fluorescence intensity of GFP. 520 
The neutralizing titer of serum and BAL from animals infected with the same A/sw/Eng/1353/09 virus 521 
and sacrificed at 14 dpi is shown in red.  522 
Fig. 5: FI6 binding to human and pig Fc receptors. Antibody and pdmH1N1 virus were pre-523 
incubated for 1 hour at 37oC and then added to the either human or pig PBMC. A) Gated on live cells, 524 
singlets and SSCA vs IgG FITC. B) and C) Gated on live cells, singlets and CD3—  CD8+ IgG FITC. 525 
Fig. 6:  ADCC activity of pig and human PBMC. MDCK cells expressing H1 HA were incubated 526 
with FI6, MPE8, immune or normal pig sera in the presence of either pig or human PBMC. ADCC was 527 
measured in triplicate by LDH release. FI6 and MPE8 mAbs were used at 10 µg/ml (left panel) or at a 528 
concentration range from 0.1 to 1000 ng/ml (right panel). Representative of three experiments. 529 
Fig. 7. Putative amino acid sequence alignment of FcR and IgG subclasses. A) Second IgG 530 
domain of human, mouse, and pig Fc receptors. B) Lower hinge and CH2 domain of human, mouse, 531 
and pig IgG subclasses. Previously reported Fc-FcR contact sites are shaded. Beta-strands are labelled 532 
and shown at top. C) Left. Model of the interaction of the Fc region of human IgG1 (green) with human 533 
FcgRIIIb (light blue) (pdb, 1t83). Fc-bound glycans are shown as orange spheres.  The L234 and L235 534 
Fc residues (purple) and the G159 residue of the FcRIIIb FG loop are identified.  Right. Modelling of 535 
the positioning of the porcine K159 residue in the FG loop and its clash with the Fc residue L235 536 
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